294 related articles for article (PubMed ID: 28754665)
1. Multiparametric Detection of Antibodies against Different EBV Antigens to Predict Risk for Nasopharyngeal Carcinoma in a High-Risk Population of China.
Chen H; Chen S; Lu J; Wang X; Li J; Li L; Fu J; Scheper T; Meyer W; Peng YH; Liu W
Cancer Prev Res (Phila); 2017 Sep; 10(9):542-550. PubMed ID: 28754665
[TBL] [Abstract][Full Text] [Related]
2. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
Guo J; Cui Z; Zheng Y; Li X; Chen Y
Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
[TBL] [Abstract][Full Text] [Related]
4. Nasopharyngeal Epstein-Barr Virus Load: An Efficient Supplementary Method for Population-Based Nasopharyngeal Carcinoma Screening.
Chen Y; Zhao W; Lin L; Xiao X; Zhou X; Ming H; Huang T; Liao J; Li Y; Zeng X; Huang G; Ye W; Zhang Z
PLoS One; 2015; 10(7):e0132669. PubMed ID: 26151639
[TBL] [Abstract][Full Text] [Related]
5. Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis.
Xia C; Zhu K; Zheng G
Int J Clin Exp Pathol; 2015; 8(12):16104-10. PubMed ID: 26884888
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.
Ji MF; Huang QH; Yu X; Liu Z; Li X; Zhang LF; Wang P; Xie SH; Rao HL; Fang F; Guo X; Liu Q; Hong MH; Ye W; Zeng YX; Cao SM
Cancer; 2014 May; 120(9):1353-60. PubMed ID: 24477877
[TBL] [Abstract][Full Text] [Related]
7. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma.
Chan KH; Gu YL; Ng F; Ng PS; Seto WH; Sham JS; Chua D; Wei W; Chen YL; Luk W; Zong YS; Ng MH
Int J Cancer; 2003 Jul; 105(5):706-9. PubMed ID: 12740922
[TBL] [Abstract][Full Text] [Related]
8. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
Luo YL; Chen H; Peng SG; Lin JH; Huang PY
Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
[TBL] [Abstract][Full Text] [Related]
9. Application of logistic regression in combination with multiple diagnostic tests for auxiliary diagnosis of nasopharyngeal carcinoma.
Jiang SQ; Liu Q
Ai Zheng; 2009 Feb; 28(2):177-80. PubMed ID: 19550133
[TBL] [Abstract][Full Text] [Related]
10. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic significance of combined detection of Epstein-Barr virus antibodies, VCA/IgA, EA/IgA, Rta/IgG and EBNA1/IgA for nasopharyngeal carcinoma.
Cai YL; Li J; Lu AY; Zheng YM; Zhong WM; Wang W; Gao JQ; Zeng H; Cheng JR; Tang MZ
Asian Pac J Cancer Prev; 2014; 15(5):2001-6. PubMed ID: 24716925
[TBL] [Abstract][Full Text] [Related]
12. [Combined detection of Epstein-Barr virus antibodies for serodiagnosis of nasopharyngeal carcinoma].
Cai YL; Zheng YM; Wang W; Wei Y; Shen XX; Cheng JR; Wu YS; Gao JQ; Zhong WM; Li J
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Dec; 30(12):2746-8. PubMed ID: 21177196
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of combined determinations of Epstein-Barr virus antibodies for nasopharyngeal carcinoma assessed with receiver operating characteristic curve based on logistic regression].
Cai YL; Zheng YM; Cheng JR; Li J; Mo YK; Zhong QY
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Oct; 23(5):384-7. PubMed ID: 20387494
[TBL] [Abstract][Full Text] [Related]
14. Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients.
Cui J; Yan W; Xu S; Wang Q; Zhang W; Liu W; Ni A
PLoS One; 2018; 13(3):e0193171. PubMed ID: 29494658
[TBL] [Abstract][Full Text] [Related]
15. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma.
Chen H; Chi P; Wang W; Li L; Luo Y; Fu J; Zhang L; Liu W
Int J Infect Dis; 2014 Aug; 25():110-5. PubMed ID: 24878579
[TBL] [Abstract][Full Text] [Related]
17. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
18. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody.
Leung SF; Tam JS; Chan AT; Zee B; Chan LY; Huang DP; Van Hasselt A; Johnson PJ; Lo YM
Clin Chem; 2004 Feb; 50(2):339-45. PubMed ID: 14684618
[TBL] [Abstract][Full Text] [Related]
19. Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum.
Cheng WM; Chan KH; Chen HL; Luo RX; Ng SP; Luk W; Zheng BJ; Ji MF; Liang JS; Sham JS; Wang DK; Zong YS; Ng MH
Int J Cancer; 2002 Feb; 97(4):489-92. PubMed ID: 11802211
[TBL] [Abstract][Full Text] [Related]
20. Polymyositis/dermatomyositis and nasopharyngeal carcinoma: the Epstein-Barr virus connection?
Chen DY; Chen YM; Lan JL; Chen HH; Hsieh CW; Wey SJ; Lu JJ
J Clin Virol; 2010 Dec; 49(4):290-5. PubMed ID: 20934910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
